DiaMedica Therapeutics Inc.
NASDAQ:DMACBiotechnology
-$0.01 today
- Market cap
- $463.49M
- Beta
- 1.00
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.65
Volume 0.21M
Average 0.19M
DMAC Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
DiaMedica Therapeutics Inc.NASDAQ: DMAC
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables growth accelerates
Q1 FY2026 accounts receivables of $43K (cash outflow) rose 152.9% year over year, ahead of the -134.1% change in trailing-twelve-month accounts receivables.
Context
- Accounts receivables increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +152.9% holds above the trailing-twelve-month pace of -134.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (22K) USD
- Year-over-year change
- -116.5%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (22K) | -116.5% |
| FY2024 | 2024-12-31 | 133K | +146.3% |
| FY2023 | 2023-12-31 | (287K) | -697.9% |
| FY2022 | 2022-12-31 | 48K | -77.1% |
| FY2021 | 2021-12-31 | 210K | — |
Accounts Receivables vs competitors
How DMAC compares with its peers on the latest reported figures
- DMAC's LTM Mar 2026 accounts receivables of $49.73K is the 6th largest of the 7 companies compared; the peer median is $1.16M.
- Its year-over-year change of -134.1% is the lowest of 4, against a peer median of -3.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $20M | — | — | 100.0% | |
| LTM Jun 2026 | $3.93M | — | — | 109.0% | |
| LTM Mar 2026 | $1.97M | -94.6% | — | 0.8% | |
| LTM Mar 2026 | $720K | +373.7% | — | 81.0% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $348K | -3.6% | — | 3.4% |
| LTM Mar 2026 | $49.73K | -134.1% | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding DMAC) | $1.16M | -3.6% | — | 81.0% | |
Competitors are the stored peer set for DMAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (13.59M) | (13.68M) | (19.38M) | (24.44M) | (32.77M) |
| Depreciation & Amortization | 24K | 25K | 30K | 39K | (899K) |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.56M | 1.5M | 1.68M | 2.09M | 3.85M |
| Change in Working Capital | (461K) | 585K | 93K | 1.51M | 675K |
| Accounts Receivables | 210K | 48K | (287K) | 133K | (22K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (590K) | 225K | 192K | 14K | 535K |
| Other Working Capital | (81K) | 312K | 188K | 1.37M | 162K |
| Other Non-Cash Items | 219K | 53K | (1.15M) | (1.27M) | 82K |
| Operating Cash Flow | (12.25M) | (11.51M) | (18.73M) | (22.08M) | (29.06M) |
| Capital Expenditures | (22K) | (81K) | (24K) | (25K) | (40K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (69.81M) | (45.68M) | (69.41M) | (50.41M) | (59.28M) |
| Sales of Investments | 49.3M | 57.3M | 51.14M | 59M | 57.13M |
| Other Investing Activities | 2K | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (20.54M) | 11.54M | (18.3M) | 8.56M | (2.19M) |
| Debt Repayment | (6K) | (6K) | (6K) | (9K) | (10K) |
| Common Stock Issued | 29.85M | 0 | 36.85M | 11.75M | 44.29M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 244K | 0 | 0 | 256K | (400K) |
| Financing Cash Flow | 30.09M | (6K) | 36.84M | 11.99M | 43.88M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (2.7M) | 21K | (185K) | (1.52M) | 12.62M |
| Free Cash Flow | (12.27M) | (11.59M) | (18.75M) | (22.1M) | (29.1M) |
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
Intrinsic Alpha fair value
Locked
Current Price
$8.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.